Tuberous Sclerosis is a genetic disease in which benign tumors grow in various parts of the body. The severity of the symptoms experienced depends on where the tumors grow. Individuals are usually diagnosed with Tuberous Sclerosis in infancy or early childhood, but those with very mild symptoms may go undiagnosed. Some symptoms include patches of light colored or thickened skin, seizures, developmental delays, communication or learning disabilities, or trouble breathing. Tuberous Sclerosis can be the underlying cause of autism and epilepsy. Tuberous Sclerosis is caused by a mutation in the TSC1 or the TSC2 gene, which normally prevent uncontrolled cell growth. The lesions most commonly grow in the skin, brain, lungs, and kidneys, and if the lesion negatively affects the role of the organ, surgery may be required. There is no cure for Tuberous Sclerosis, but other treatments include medication and educational and occupational therapy.
Tuberous Sclerosis Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Tuberous Sclerosis below!
For more information on how to use Laverne, please read the How to Guide.
We have 1718 products for the study of Tuberous Sclerosis that can be applied to Flow Cytometry, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Tuberous Sclerosis is also known as tuberous sclerosis, tuberous sclerosis complex, bourneville phakomatosis, sclerosis tuberosa, tuberous sclerosis syndrome (disorder), bourneville pringle syndrome, bourneville's disease, tuberous sclerosis 1, bourneville syndrome, tuberous sclerosis-1, phakomatosis ts, tsc1.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.